会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Cancerous B cell treatment using substituted nucleoside derivatives
    • 使用取代的核苷衍生物进行癌细胞B细胞治疗
    • US5476659A
    • 1995-12-19
    • US151142
    • 1993-11-12
    • Michael G. GoodmanLawrence D. Piro
    • Michael G. GoodmanLawrence D. Piro
    • A61K35/74A61K47/48C07H19/16A61K39/39A61K31/70C12N5/06C12N5/08
    • A61K31/70A61K47/48276C07H19/16C12N5/0093C12N2501/06C12N2501/999Y10S514/908
    • Processes for the killing of cancerous B cells, and particularly chronic lymphocytic leukemia (CLL) cells are disclosed. In one process, cancerous B cells that do not proliferate when contacted with an immune response-enhancing agent are contacted with an amount of such an agent sufficient to cause peripheral CLL cells to undergo blast transformation and proliferation. The contacted cells are then maintained for a time period sufficient for them to die from that contact. Further contacting of those cells with a cytotoxic amount of an anti-cancer drug or cytotoxic conjugate enhances the death of those cancer cells. In another process, peripheral CLL cells that proliferate on contact with an immune response-enhancing-agent are contacted with a proliferation-inducing amount of such an agent. The contacted cells are maintained for a time period sufficient to undergo blast transformation and proliferation, and the blasts are then contacted with a cytotoxic amount of an anti-cancer drug or cytotoxic conjugate and maintained.
    • 公开了杀死癌性B细胞,特别是慢性淋巴细胞性白血病(CLL)细胞的方法。 在一个过程中,当与免疫应答增强剂接触时不增殖的癌性B细胞与足以引起外周CLL细胞经历blast转化和增殖的量的这种试剂接触。 然后将接触的细胞保持足以使它们从该接触死亡的时间段。 这些细胞与细胞毒性量的抗癌药物或细胞毒性缀合物的进一步接触增强了那些癌细胞的死亡。 在另一个方法中,与免疫应答增强剂接触时增殖的外周CLL细胞与增殖诱导量的这种试剂接触。 将接触的细胞保持足以进行细胞转化和增殖的时间段,然后将母细胞与细胞毒性量的抗癌药物或细胞毒性缀合物接触并保持。